TriangleNCT01159067 · OUTCOME
Number of Patients With LPI Below 0.5 Umol/L After Treatment
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- Measure
- Not reported
- Unit
- Not reported
- Interval / dispersion
- Not reported
- Time frame
- Assessed through 6 months from the start of treatment
What was measured
In patients with LPI values above threshold 0.5umol/L at baseline, number of patients had LPI suppressed below this value after treatment. Measurement of LPI is done on plasma specimens.
Analysis population: No patient had elevated LPI level above 0.5umol/L at baseline.
Groups in this outcome
Arm I
Patients receive oral deferasirox once daily for up to 6 months in the absence of unacceptable toxicity.
| Group | Source count |
|---|---|
| Arm I | 0 |
Reported measurements
No numerical measurement classes were posted for this outcome. Missing is not zero.
Complete source fields
- denoms
- counts
- group Id
- OG000
- value
- 0
- units
- Participants
- description
- In patients with LPI values above threshold 0.5umol/L at baseline, number of patients had LPI suppressed below this value after treatment. Measurement of LPI is done on plasma specimens.
- groups
- description
- Patients receive oral deferasirox once daily for up to 6 months in the absence of unacceptable toxicity.
- id
- OG000
- title
- Arm I
- population Description
- No patient had elevated LPI level above 0.5umol/L at baseline.
- reporting Status
- POSTED
- time Frame
- Assessed through 6 months from the start of treatment
- title
- Number of Patients With LPI Below 0.5 Umol/L After Treatment
- type
- SECONDARY
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice